Drugs / CTH522
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03926728 | Feb 2020 → Feb 2022 | trachoma | Statens Serum Institut | Completed | No outcome recorded |
| Phase 1 | NCT02787109 | Jul 2016 → Jul 2017 | chlamydia trachomatis infectious disease | Statens Serum Institut | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTH522 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03926728 ↗ |
| Modality | Protein / enzyme biologic | “novel chlamydia vaccine based on a recombinant protein subunit (CTH522)” PMID 31416692 ↗ Aug 2019 |
| Route | Intramuscular | “Participants received three intramuscular injections of 85 μg vaccine (with adjuvant) or placebo to the deltoid region of the arm at 0, 1, and 4 months, followed by two...” PMID 31416692 ↗ Aug 2019 |
| Route | Intranasal | “Participants received three intramuscular injections of 85 μg vaccine (with adjuvant) or placebo to the deltoid region of the arm at 0, 1, and 4 months, followed by two...” PMID 31416692 ↗ Aug 2019 |